Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”. Fitz, N. F., Cronican, A. A., Lefterov, I., & Koldamova, R. Science, 340(6135):924--924, May, 2013.
Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models” [link]Paper  doi  abstract   bibtex   
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrated in a mouse model for Alzheimer’s disease (AD) that treatment of APP/PS1ΔE9 mice with bexarotene decreased Aβ pathology and ameliorated memory deficits. We confirm the reversal of memory deficits in APP/PS1ΔE9 mice expressing human APOE3 or APOE4 to the levels of their nontransgenic controls and the significant decrease of interstitial fluid Aβ, but not the effects on amyloid deposition.
@article{fitz_comment_2013,
	title = {Comment on “{ApoE}-{Directed} {Therapeutics} {Rapidly} {Clear} β-{Amyloid} and {Reverse} {Deficits} in {AD} {Mouse} {Models}”},
	volume = {340},
	copyright = {Copyright © 2013, American Association for the Advancement of Science},
	issn = {0036-8075, 1095-9203},
	url = {http://science.sciencemag.org/content/340/6135/924.3},
	doi = {10.1126/science.1235809},
	abstract = {Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrated in a mouse model for Alzheimer’s disease (AD) that treatment of APP/PS1ΔE9 mice with bexarotene decreased Aβ pathology and ameliorated memory deficits. We confirm the reversal of memory deficits in APP/PS1ΔE9 mice expressing human APOE3 or APOE4 to the levels of their nontransgenic controls and the significant decrease of interstitial fluid Aβ, but not the effects on amyloid deposition.},
	language = {en},
	number = {6135},
	urldate = {2016-09-16TZ},
	journal = {Science},
	author = {Fitz, Nicholas F. and Cronican, Andrea A. and Lefterov, Iliya and Koldamova, Radosveta},
	month = may,
	year = {2013},
	pmid = {23704552},
	pages = {924--924}
}
Downloads: 0